GAIN

Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – A phase III study utilizing the German Registry of Incidental Gallbladder Carcinoma Platform (GR) – The AIO/ CALGP/ ACO- GAIN-Trial

III

interventionell

National

Cisplatin, Gemcitabin

Status: In Rekrutierung

Zeitraum

2019

2023

Zentren

50

37

Zentren gesucht

Patienten

300

32

30.03.2022

Klinische Settings

peri-operativ

front line

kurativ

Beteiligte

AIO-Arbeitsgruppen

Sponsor

Institute of Clinical Cancer Research (IKF) Krankenhaus Nordwest

Kooperierende Fachgesellschaft(en)

ACO
DGAV-CALGP

Förderer

DFG

Identifier

AIO-HEP-0118/ass

GAIN/GEM/CIS

2017-004444-38

Kontakt

Leitung

PD Dr. med. Thorsten Oliver Götze

Ansprechpartner*in

PD Dr. med. Thorsten Oliver Götze
Telefon +49 69 7601-4420
E-Mail Goetze.Thorsten@khnw.de